Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients: Review of the literature and a proposal for tailored treatment

References

• Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet. 2007;369:2031–41.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.
   PubMed Web of Science ®Google Scholar
• McGuire V, Longstreth WT, Koepsell TD, van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington State. Neurology. 1996;47:571–3.
   PubMed Web of Science ®Google Scholar
• Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: a review of the aetiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:48–57.
   PubMed Web of Science ®Google Scholar
• Millul A, Beghi E, Longroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population based registry. Neuroepidemiology. 2005;25:114–9.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler. 2007;8:195–213.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Abrahams S, Borasio GD, Carvalho M, Chio A, van Damme P, et al. EFNS guidelines on the clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force. Eur Neurol. 2012; 19:360–75.
   Google Scholar
• Squires N, Wills A, Rowson J. The management of drooling in adults with neurological conditions. Curr Opin Otolaryngol Head Neck Surg. 2012;20:171–6.
   PubMedGoogle Scholar
• Neppelberg E, Haugen DF, Thorsen L, Tysnes OB. Radiotherapy reduces sialorrhoea in amyotrophic lateral sclerosis. European Journal of Neurology. 2007;14:1373–7.
   PubMed Web of Science ®Google Scholar
• Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. J Physiol. 1949;109: 10–24.
   PubMed Web of Science ®Google Scholar
• MacKenzie I, Bumstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience. 1982;7:997–1006.
   PubMed Web of Science ®Google Scholar
• Bushara KO. Sialorrhoea in amyotrophic lateral sclerosis: a hypothesis of a new treatment. Botulinum toxin A injections of the parotid glands. Med Hypotheses. 1997;48:337–9.
   PubMed Web of Science ®Google Scholar
• AAN (American Academy of Neurology). Clinical Practice Guideline Process Manual, 2011 Ed. St. Paul, MN: The American Academy of Neurology.
   Google Scholar
• Evangelos A, Michael R, Theodoros A, Vasiliki Z, Thomas Z, Ioannis E. Volume matters: the influence of different botulinum toxin-A dilutions for sialorrhoea in amyotrophic lateral sclerosis. Muscle Nerve. 2013;47:276–8.
   PubMedGoogle Scholar
• Gilio F, Iacovelli E, Frasca V, Gabriele M, Giacomelli E, Picchiori F, et al. Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. Amyotroph Lateral Scler. 2010; 11:359–63.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhoea in ALS patients. Muscle Nerve. 2009;39:137–43.
   PubMed Web of Science ®Google Scholar
• Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M. Botulinum toxin type B improves sialorrhoea and quality of life in bulbar-onset amyotrophic lateral sclerosis. J Neurol. 2008;255:545–50.
   PubMed Web of Science ®Google Scholar
• Verma A, Steele J. Botulinum toxin improves sialorrhoea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve. 2006;34:235–7.
   PubMed Web of Science ®Google Scholar
• Manrique D. Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis. Braz J Otorhinolaryngol. 2005;71:566–9.
   PubMedGoogle Scholar
• Scott KR, Kothari MJ, Venkatesh YS, Murphy T, Simmons Z. Parotid gland injections of botulinum toxin A are effective in treating sialorrhoea in amyotrophic lateral sclerosis. J Clin Neuromusc Dis. 2005;7:62–5.
   PubMedGoogle Scholar
• Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:121–3.
   PubMed Web of Science ®Google Scholar
• Guidubaldi A, Fasano A, Lalongo T, Piano C, Pompili M, Mascianà R, et al. Botulinum Toxin A Versus B in Sialorrhoea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease. Mov Disord. 2011;26:313–9.
   PubMed Web of Science ®Google Scholar
• Møller E, Karlsborg M, Bardow A, Lykkeaa J, Nissen FH, Bakke M. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms. Acta Odontol Scand. 2011; 69:151–7.
   PubMed Web of Science ®Google Scholar
• Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A, et al. Botulinum toxin B ultrasound-guided injections for sialorrhoea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord. 2007;13: 299–303.
   PubMedGoogle Scholar
• Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279–81.
   PubMed Web of Science ®Google Scholar
• Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 2001;70:538–40.
   PubMed Web of Science ®Google Scholar
• Meijer JW, van Kuijk AA, Geurts AC, Schelhaas HJ, Zwarts MJ. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2008;87:321–4.
   PubMed Web of Science ®Google Scholar
• Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001;190:95–7.
   PubMed Web of Science ®Google Scholar
• Lorenzano C, Bagnato S, Gilio F, Fabbrini G, Berardelli A. No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm. Neurotox Res. 2006;9:141–4.
   PubMed Web of Science ®Google Scholar
• Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol. 2004;140:1351–4.
   PubMed Web of Science ®Google Scholar
• Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology. 2000;54: 244–7.
   PubMedGoogle Scholar
• Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg. 2004; 106:93–6.
   PubMed Web of Science ®Google Scholar
• Lim M, Mace A, Nouraei SA, Sandhu G. Botulinum toxin in the management of sialorrhoea: a systematic review. Clin Otolaryngol. 2006;31:267–72.
   PubMed Web of Science ®Google Scholar
• Enfors BO. The parotid and submandibular secretion in man. Quantative recordings of the normal and pathological activity. Acta Otolaryngol Suppl. 1962;172:1–67.
   PubMedGoogle Scholar
• Suskind DL, Tilton A. Clinical study of botulinum A toxin in the treatment of sialorrhoea in children with cerebral palsy. Laryngoscope. 2002;112:73–81.
   PubMed Web of Science ®Google Scholar
• Basciani M, di Rienzo F, Fontana A, Copetti M, Pellegrini F. Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol. 2011;53:559–64.
   PubMed Web of Science ®Google Scholar